ERBB2 and breast carcinoma: A prospective cohort study on 134,122 multiethnic postmenopausal women in the US, aged 50 to 79 years old, showed no significant impact from THs status on Surveillance, Epidemiology, and End Results (SEER) stages, histologic types, morphologic grades, ER status, PR status, or the human epidermal growth factor receptor 2 (HER2) status of breast cancer [75].